<unk>  is a a combination of three direct-acting hepatitis C virus antiviral agents with distinct mechanisms of action that is FDA approved for the treatment of adult patients with chronic hepatitis C virus (HCV). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, nausea, pruritus, other skin reactions, insomnia and asthenia.
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Sofosbuvir / velpatasvir
Sofosbuvir / velpatasvir / voxilaprevir
Ledipasvir / sofosbuvir
Elbasvir / grazoprevir
Glecaprevir / pibrentasvir
Dolutegravir / rilpivirine
Bictegravir / emtricitabine / tenofovir alafenamide